The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model

Posaconazole is more active than fluconazole against Candida albicans in vitro and is approved for the treatment of oropharyngeal candidiasis but not for that of invasive candidiasis (IC). Here, we explored the efficacy of posaconazole against C. albicans in an in vitro pharmacokinetic/pharmacodynam...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Beredaki, Maria-Ioanna, Arendrup, Maiken Cavling, Andes, David, Mouton, Johan W., Meletiadis, Joseph
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2021
Témata:
Susceptibility
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8097413/
https://ncbi.nlm.nih.gov/pubmed/33468486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01292-20
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky